echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > A delegation from the Chinese Association for the promotion of drugs held talks with the British Columbia government of Canada

    A delegation from the Chinese Association for the promotion of drugs held talks with the British Columbia government of Canada

    • Last Update: 2013-07-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: from July 19, 2013 to July 19, 2013, the delegation led by song Ruilin was invited to hold talks with representatives of British Columbia government at Vancouver Asia Pacific Economic and Trade Center The delegation was led by Ren Wuxian, chairman of Yabao Pharmaceutical Group, Dai Dongsheng, director of R & D Department of Yabao Pharmaceutical Group, Jin Quanyuan, director of scientific research department of Shenyang Pharmaceutical University, Li Minghua, deputy general manager of Shanxi Zhendong Pharmaceutical Co., Ltd., Xie Licheng, deputy general manager of Changzhou Fangyuan Pharmaceutical Co., Ltd., Zhao Jing, deputy general manager of R & D center of Meiluo Pharmaceutical Co., Ltd., ou lingyunyi, technical director of Guizhou Xinbang Pharmaceutical Co., Ltd It is composed of Chen Changxiong, Executive Deputy Secretary General of the China Association for the promotion of drugs, Wang Xin, deputy director of international affairs, etc The Canadian participants included Jason Han, senior manager of the British Columbia International Trade Department, don Enns, President of the British Columbia Biotechnology Association (lsbc), Bryan Henderson, senior consultant of PricewaterhouseCoopers Canada, Jimmy Mitchell, vice president of advantage BC, the British Columbia International Economic and Trade Promotion Agency Mei Jianping, science and technology consul of the Chinese Consulate General in Vancouver, also attended the meeting During the talks, Jason Han, senior manager of British Columbia International Trade Department, first extended a warm welcome on behalf of the British Columbia government to the visit of the delegation of China Council for the promotion of medicine, and introduced the development of biomedical industry in British Columbia According to song Ruilin, the executive chairman, British Columbia has a huge advantage in basic research of pharmaceutical technology, which forms a good complement with China's pharmaceutical industry In the future, the two sides can further deepen understanding and continuously carry out in-depth cooperation Mei Jianping, science and technology consul of the Chinese Consulate General in Vancouver, said in his speech that British Columbia has unique advantages in the field of biotechnology He hoped that Chinese enterprises would pay attention to innovation projects and cooperation opportunities of British Columbia, and the Consulate General would actively promote cooperation between the two sides Later, Bryan Henderson, senior consultant of PricewaterhouseCoopers Canada, Li Xiaojing, senior manager and Ted Zhou, manager, introduced the Canadian tax legal system and tax relief system to the delegation in detail Jimmy Mitchell, vice president of advantage BC, a British Columbia International Economic and Trade Promotion Agency, explained the preferential tax policies of British Columbia to encourage pharmaceutical R & D innovation "Excellent tax BC" is an organization established by the British Columbia government in 1986 to attract foreign enterprises and provide tax relief services for foreign enterprises Only by joining this organization can foreign enterprises enjoy tax preference The delegation was very interested in Canada's preferential tax policies, especially the tax relief policies to encourage the innovation of medical science and technology, and had a heated discussion with the speakers So far, the visit to Canada by the delegation of the China Council for the promotion of drugs has been a complete success All members feel that the exchange and visit are arranged in a very compact way The content of official activities is rich and practical, which has broadened their horizons and broadened their thinking It is very helpful for the future pharmaceutical innovation work Through this event, CFDA has established close ties with the Canadian government, association organizations, pharmaceutical enterprises and scientific research institutions, and opened a new chapter of exchanges and cooperation between China and Canada's pharmaceutical industry Don Enns, chairman of lsbc, said that he hoped to establish a long-term strategic partnership with China Council for the promotion of medicine and hold some activities together regularly every year to promote the normalization and deepening of exchanges and cooperation between China and Canada in the pharmaceutical industry A group photo of representatives of the China Canada meeting at the meeting site between the delegation of the China Council for the promotion of drugs and the British Columbia government
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.